Abstract
Deregulated miR-379/miR-656 cluster expression is considered as important for carcinogenesis and can be used as a potential prognostic marker. Hence, the meta-analysis was conducted to test the utility of miR-379/miR-656 cluster as a prognostic marker in various cancers. A literature search was performed using Web of Science, PubMed and Cochrane Library to obtain relevant studies and were subjected to various subgroup and bioinformatics analyses. Selected twenty-three studies contained 13 cancer types comprising of 3294 patients from 7 nations. Univariate and multivariate data showed an association of high expression of miRNAs with the poor prognosis of cancer patients (p < 0.001). The subgroup analysis showed that lung cancer, breast cancer and papillary renal cell carcinoma (p < 0.001) have a negative association with the survival of patients. Our study is the first meta-analysis showing the association of miR-379/miR-656 cluster expression and overall survival, suggesting its potential as a prognostic indicator in multiple cancers.
Similar content being viewed by others
Abbreviations
- BRCA:
-
Breast cancer
- Chr:
-
Chromosome
- Chr14MC:
-
MiR-379/miR-656 cluster
- 95% CI:
-
Confidence interval at 95%
- CESC:
-
Cervical squamous cell carcinoma and endocervical adenocarcinoma
- COAD:
-
Colon adenocarcinoma
- CRCA:
-
Colorectal cancer
- DFS:
-
Disease free survival
- FDA:
-
Food and Drug Administration
- FFPET:
-
Formalin-fixed paraffin-embedded tissue
- HNSCC:
-
Head and neck squamous cell carcinoma
- HR:
-
Hazard ratio
- ICC:
-
Cervical cancer
- ISH:
-
In situ hybridization
- LIHC:
-
Liver hepatocellular carcinoma
- LUAD:
-
Lung adenocarcinoma
- MBL:
-
Medulloblastoma
- miRNA:
-
MicroRNA
- NBL:
-
Neuroblastoma
- NSCLC:
-
Non-small cell lung cancer
- OS:
-
Overall survival
- OV:
-
Ovarian cancer
- PAAD:
-
Pancreatic adenocarcinoma
- PFS:
-
Progression free survival
- pRCC:
-
Papillary renal cell carcinoma
- PRISMA:
-
Preferred items for systematic reviews and meta-analyses
- qRT-PCR:
-
Quantitative real-time polymerase chain reaction
- RFS:
-
Regression free survival
- STAD:
-
Stomach adenocarcinoma (gastric cancer)
- TCGA:
-
The cancer genome atlas
- TTD:
-
Therapeutic target database
- EMT:
-
Epithelial to mesenchymal transition
- DDR:
-
DNA damage response
- PDGF-R:
-
Platelet-derived growth factor receptors
- TGF:
-
Transforming growth factor
References
Adams BD, Kasinski AL, Slack FJ (2014) Aberrant regulation and function of microRNAs in cancer. Curr Biol 24:R762–R776. https://doi.org/10.1016/j.cub.2014.06.043
Varghese VK, Shukla V, Kabekkodu SP et al (2018) DNA methylation regulated microRNAs in human cervical cancer. Mol Carcinog 57:370–382. https://doi.org/10.1002/mc.22761
Shah MY, Ferrajoli A, Sood AK et al (2016) microRNA therapeutics in cancer: an emerging concept. EBioMedicine 12:34–42. https://doi.org/10.1016/j.ebiom.2016.09.017
Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20:460–469. https://doi.org/10.1016/j.molmed.2014.06.005
Griffiths-Jones S (2006) miRBase: the microRNA sequence database. Methods Mol Biol 342:129–138. https://doi.org/10.1385/1-59745-123-1:129
Kabekkodu SP, Shukla V, Varghese VK et al (2018) Clustered miRNAs and their role in biological functions and diseases. Biol Rev 93:1955–1986. https://doi.org/10.1111/brv.12428
Glazov EA, McWilliam S, Barris WC, Dalrymple BP (2008) Origin evolution, and biological role of miRNA cluster in DLK-DIO3 genomic region in placental mammals. Mol Biol Evol 25:939–948. https://doi.org/10.1093/molbev/msn045
Tsai K-W, Kao H-W, Chen H-C, et al (2009) Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells. Epigenetics 587 Epigenetics 4:587–592. https://doi.org/10.4161/epi.4.8.10230
Edwards CA, Mungall AJ, Matthews L et al (2008) The evolution of the DLK1-DIO3 imprinted domain in mammals. PLoS Biol 6:1292–1305. https://doi.org/10.1371/journal.pbio.0060135
González-Vallinas M, Rodríguez-Paredes M, Albrecht M et al (2018) Epigenetically regulated chromosome 14q32 miRNA cluster induces metastasis and predicts poor prognosis in lung adenocarcinoma patients. Mol Cancer Res 16:390–402. https://doi.org/10.1158/1541-7786.MCR-17-0334
Shahar T, Granit A, Zrihan D et al (2016) Expression level of miRNAs on chromosome 14q32.31 region correlates with tumor aggressiveness and survival of glioblastoma patients. J Neurooncol 130:413–422. https://doi.org/10.1007/s11060-016-2248-0
Kumar A, Nayak S, Pathak P et al (2018) Identification of miR-379/miR-656 (C14MC) cluster downregulation and associated epigenetic and transcription regulatory mechanism in oligodendrogliomas. J Neurooncol 139:23–31. https://doi.org/10.1007/s11060-018-2840-6
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264. https://doi.org/10.7326/0003-4819-151-4-200908180-00135
Review Manager (RevMan) (2014) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration
Suurmond R, van Rhee H, Hak T (2017) Introduction, comparison, and validation of meta-essentials: a free and simple tool for meta-analysis. Res Synth Methods 8:537–553. https://doi.org/10.1002/jrsm.1260
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188. https://doi.org/10.1016/0197-2456(86)90046-2
Lewis S, Clarke M (2001) Forest plots: trying to see the wood and the trees. BMJ 322:1479–1480
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088. https://doi.org/10.2307/2533446
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634. https://doi.org/10.1136/BMJ.315.7109.629
Aguirre-Gamboa R, Trevino V (2014) SurvMicro: assessment of miRNA-based prognostic signatures for cancer clinical outcomes by multivariate survival analysis. Bioinformatics 30:1630–1632. https://doi.org/10.1093/bioinformatics/btu087
Goswami CP, Nakshatri H (2012) PROGmiR: a tool for identifying prognostic miRNA biomarkers in multiple cancers using publicly available data. J Clin Bioinform 2:23. https://doi.org/10.1186/2043-9113-2-23
Chou CH, Shrestha S, Yang CD et al (2018) MiRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res 46:D296–D302. https://doi.org/10.1093/nar/gkx1067
Wang J, Duncan D, Shi Z, Zhang B (2013) WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res 41:W77–W83. https://doi.org/10.1093/nar/gkt439
Anaya J (2016) OncoLnc: linking TCGA survival data to mRNAs miRNAs and lncRNAs. PeerJ Comput Sci 2:e67. https://doi.org/10.7717/peerj-cs.67
Fiannaca A, La Rosa M, La Paglia L, Urso A (2018) miRTissue: a web application for the analysis of miRNA-target interactions in human tissues. BMC Bioinform 19:434. https://doi.org/10.1186/s12859-018-2418-5
Krzywinski M, Schein J, Birol I et al (2009) Circos: an information aesthetic for comparative genomics. Genome Res 19:1639–1645. https://doi.org/10.1101/gr.092759.109
Ritchie W, Flamant S, Rasko JEJ (2010) mimiRNA: a microRNA expression profiler and classification resource designed to identify functional correlations between microRNAs and their targets. Bioinformatics 26:223–227. https://doi.org/10.1093/bioinformatics/btp649
Yang Z, Ren F, Liu C et al (2010) dbDEMC: a database of differentially expressed miRNAs in human cancers. BMC Genom 11(Suppl 4):S5. https://doi.org/10.1186/1471-2164-11-S4-S5
Panwar B, Omenn GS, Guan Y (2017) miRmine: a database of human miRNA expression profiles. Bioinformatics 33:1554–1560. https://doi.org/10.1093/bioinformatics/btx019
Zhang H, Wang Z, Ma R et al (2018) MicroRNAs as biomarkers for the progression and prognosis of colon carcinoma. Int J Mol Med 42:2080–2088
Ji W, Sun B, Su C (2017) Targeting microRNAs in cancer gene therapy. Genes (Basel). https://doi.org/10.3390/genes8010021
Chen Y, Gao D-Y, Huang L (2015) In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev 81:128–141. https://doi.org/10.1016/J.ADDR.2014.05.009
Di Martino MT, Rossi M, Caracciolo D et al (2016) Mir-221/222 are promising targets for innovative anticancer therapy. Expert Opin Ther Targets 20:1099–1108. https://doi.org/10.1517/14728222.2016.1164693
Saito T, Hara S, Kato T et al (2018) A tandem repeat array in IG-DMR is essential for imprinting of paternal allele at the Dlk1-Dio3 domain during embryonic development. Hum Mol Genet 27:3283–3292. https://doi.org/10.1093/hmg/ddy235
Rago L, Beattie R, Taylor V, Winter J (2014) MiR379-410 cluster miRNAs regulate neurogenesis and neuronal migration by fine-tuning N-cadherin. EMBO J 33:906–920. https://doi.org/10.1002/embj.201386591
Welten SMJ, Bastiaansen AJNM, De Jong RCM et al (2014) Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-494, and miR-495 increases neovascularization and blood flow recovery after ischemia. Circ Res 115:696–708. https://doi.org/10.1161/CIRCRESAHA.114.304747
Labialle S, Marty V, Bortolin-Cavaille M-L et al (2014) cluster at the imprinted Dlk1-Dio3 domain controls neonatal metabolic adaptation. EMBO J 33:2216–2230. https://doi.org/10.15252/embj.201387038
Laddha SV, Nayak S, Paul D et al (2013) Genome-wide analysis reveals downregulation of miR-379/miR-656 cluster in human cancers. Biol Direct 8:10. https://doi.org/10.1186/1745-6150-8-10
Nayak S, Aich M, Kumar A et al (2018) Novel internal regulators and candidate miRNAs within miR-379/miR-656 miRNA cluster can alter cellular phenotype of human glioblastoma. Sci Rep 8:7673. https://doi.org/10.1038/s41598-018-26000-8
Olaru AV, Ghiaur G, Yamanaka S et al (2011) MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology 54:2089–2098. https://doi.org/10.1002/hep.24591
Guo M, Jiang Z, Zhang X et al (2014) miR-656 inhibits glioma tumorigenesis through repression of BMPR1A. Carcinogenesis 35:1698–1706. https://doi.org/10.1093/carcin/bgu030
Liao G, Chen F, Zhong J, Jiang X (2018) MicroRNA-539 inhibits the proliferation and invasion of bladder cancer cells by regulating IGF-1R. Mol Med Rep 17:4917–4924. https://doi.org/10.3892/mmr.2018.8497
Zhang YF, Yu Y, Song WZ et al (2016) miR-410-3p suppresses breast cancer progression by targeting Snail. Oncol Rep 36:480–486. https://doi.org/10.3892/or.2016.4828
Su X, Zhang L, Li H et al (2017) MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion. Oncol Lett 13:1932–1938. https://doi.org/10.3892/ol.2017.5644
Gururajan M, Josson S, Chu GCY et al (2014) MiR-154* and miR-379 in the DLK1-DIO3 MicroRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer. Clin Cancer Res 20:6559–6569. https://doi.org/10.1158/1078-0432.CCR-14-1784
Gotzmann J, Fischer ANM, Zojer M et al (2006) A crucial function of PDGF in TGF-β-mediated cancer progression of hepatocytes. Oncogene 25:3170–3185. https://doi.org/10.1038/sj.onc.1209083
Mittal V (2016) In: Ahmad A, Gadgeel SM (eds) Epithelial mesenchymal transition in aggressive lung cancers. Springer International Publishing, Cham, pp 37–56
Hamilton G, Rath B (2017) Mesenchymal-epithelial transition and circulating tumor cells in small cell lung cancer. Advances in experimental medicine and biology. Springer, Cham, pp 229–245
Chai J, Dong W, Xie C et al (2015) MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD. IUBMB Life 67:191–201. https://doi.org/10.1002/iub.1361
Zhao H, Diao C, Wang X et al (2018) MiR-543 promotes migration, invasion and epithelial-mesenchymal transition of esophageal cancer cells by targeting phospholipase A2 group IVA. Cell Physiol Biochem 48:1595–1604. https://doi.org/10.1159/000492281
Peng Y, He X, Chen H et al (2018) Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway. Biosci Rep 38:BSR20181051. https://doi.org/10.1042/BSR20181051
Lou C, Xiao M, Cheng S et al (2016) MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1α expression. Cell Death Dis 7:e2159. https://doi.org/10.1038/cddis.2016.27
Wu H, Li J, Guo E et al (2018) MiR-410 acts as a tumor suppressor in estrogen receptor-positive breast cancer cells by directly targeting ERLIN2 via the ERS pathway. Cell Physiol Biochem 48:461–474. https://doi.org/10.1159/000491777
Wang Q, Lv L, Li Y, Ji H (2018) MicroRNA-655 suppresses cell proliferation and invasion in oral squamous cell carcinoma by directly targeting metadherin and regulating the PTEN/AKT pathway. Mol Med Rep 18:3106–3114. https://doi.org/10.3892/mmr.2018.9292
Zhao J, Xu J, Zhang R (2018) MicroRNA-539 inhibits colorectal cancer progression by directly targeting SOX4. Oncol Lett 16:2693–2700. https://doi.org/10.3892/ol.2018.8892
Lin H, Huang ZP, Liu J et al (2018) MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN. Sci Rep 8:10461. https://doi.org/10.1038/s41598-018-28519-2
Li L, Zhang H (2017) MicroRNA-379 inhibits cell proliferation and invasion in glioma via targeting metadherin and regulating PTEN/AKT pathway. Mol Med Rep 17:4049–4056. https://doi.org/10.3892/mmr.2017.8361
Zhao Z, Qin L, Li S (2016) miR-411 contributes the cell proliferation of lung cancer by targeting FOXO1. Tumor Biol 37:5551–5560. https://doi.org/10.1007/s13277-015-4425-8
Li J, Xu X, Meng S et al (2017) MET/SMAD3/SNAIL circuit mediated by miR-323a-3p is involved in regulating epithelial-mesenchymal transition progression in bladder cancer. Cell Death Dis 8:e3010. https://doi.org/10.1038/cddis.2017.331
Liu J, Jiang J, Hui X et al (2018) Mir-758-5p suppresses glioblastoma proliferation, migration and invasion by targeting ZBTB20. Cell Physiol Biochem 48:2074–2083. https://doi.org/10.1159/000492545
Jiang W, Liu J, Xu T, Yu X (2016) MiR-329 suppresses osteosarcoma development by downregulating Rab10. FEBS Lett 590:2973–2981. https://doi.org/10.1002/1873-3468.12337
Shen L, Du X, Ma H, Mei S (2017) miR-1193 suppresses the proliferation and invasion of human T-cell leukemia cells through directly targeting the transmembrane 9 superfamily 3 (TM9SF3). Oncol Res 25:1643–1651. https://doi.org/10.3727/096504017X14908284471361
Jiang X, Huang H, Li Z et al (2012) MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci USA 109:19397–19402. https://doi.org/10.1073/pnas.1217519109
Lu M, Wang C, Chen W et al (2018) miR-654-5p targets GRAP to promote proliferation, metastasis, and chemoresistance of oral squamous cell carcinoma through Ras/MAPK signaling. DNA Cell Biol 37:381–388. https://doi.org/10.1089/dna.2017.4095
An N, Luo X, Zhang M, Yu R (2017) MicroRNA-376b promotes breast cancer metastasis by targeting Hoxd10 directly. Exp Ther Med 13:79–84. https://doi.org/10.3892/etm.2016.3942
Xue Z, Zhao J, Niu L et al (2015) Up-regulation of MiR-300 promotes proliferation and invasion of osteosarcoma by targeting BRD7. PLoS ONE 10:e0127682. https://doi.org/10.1371/journal.pone.0127682
Xu Y, He J, Wang Y et al (2015) miR-889 promotes proliferation of esophageal squamous cell carcinomas through DAB2IP. FEBS Lett 589:1127–1135. https://doi.org/10.1016/j.febslet.2015.03.027
Yao H, Xia D, Li Z-L et al (2018) MiR-382 functions as tumor suppressor and chemosensitizer in colorectal cancer. Biosci Rep. https://doi.org/10.1042/BSR20180441
Lin X, Yang Z, Zhang P et al (2016) miR-154 inhibits migration and invasion of human non-small cell lung cancer by targeting ZEB2. Oncol Lett 12:301–306. https://doi.org/10.3892/ol.2016.4577
Alvarado S, Wyglinski J, Suderman M et al (2013) Methylated DNA binding domain protein 2 (MBD2) coordinately silences gene expression through activation of the microRNA hsa-mir-496 promoter in breast cancer cell line. PLoS ONE 8:e74009. https://doi.org/10.1371/journal.pone.0074009
Liu W-Y, Yang Z, Sun Q et al (2018) miR-377-3p drives malignancy characteristics via upregulating GSK-3β expression and activating NF-κB pathway in hCRC cells. J Cell Biochem 119:2124–2134. https://doi.org/10.1002/jcb.26374
Lu Y-J, Liu R-Y, Hu K, Wang Y (2016) MiR-541-3p reverses cancer progression by directly targeting TGIF2 in non-small cell lung cancer. Tumour Biol 37:12685–12695. https://doi.org/10.1007/s13277-016-5241-5
Yu H, Xing H, Han W et al (2017) MicroRNA-409-5p is upregulated in breast cancer and its downregulation inhibits cancer development through downstream target of RSU1. Tumour Biol 39:1010428317701647. https://doi.org/10.1177/1010428317701647
Li P, Dong M, Wang Z (2018) Downregulation of TSPAN13 by miR-369-3p inhibits cell proliferation in papillary thyroid cancer (PTC). Bosn J basic Med Sci. https://doi.org/10.17305/bjbms.2018.2865
Xia B, Li H, Yang S et al (2016) MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression. Tumor Biol 37:9157–9167. https://doi.org/10.1007/s13277-016-4805-8
Yanaka Y, Muramatsu T, Uetake H et al (2015) miR-544a induces epithelial-mesenchymal transition through the activation of WNT signaling pathway in gastric cancer. Carcinogenesis 36:1363–1371. https://doi.org/10.1093/carcin/bgv106
Ma M, He M, Jiang Q et al (2016) MiR-487a promotes TGF-β1-induced EMT, the migration and invasion of breast cancer cells by directly targeting MAGI2. Int J Biol Sci 12:397–408. https://doi.org/10.7150/ijbs.13475
Li J, Wang Y, Luo J et al (2012) miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett 586:3761–3765. https://doi.org/10.1016/j.febslet.2012.09.016
Lian H-W, Zhou Y, Jian Z-H, Liu R-Z (2015) MiR-323-5p acts as a tumor suppressor by targeting the insulin-like growth factor 1 receptor in human glioma cells. Asian Pac J Cancer Prev 15:10181–10185. https://doi.org/10.7314/APJCP.2014.15.23.10181
Swarbrick A, Woods SL, Shaw A et al (2010) miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med 16:1134–1140. https://doi.org/10.1038/nm.2227
Dini P, Daels P, Loux SC et al (2018) Kinetics of the chromosome 14 microRNA cluster ortholog and its potential role during placental development in the pregnant mare. BMC Genom 19:954. https://doi.org/10.1186/s12864-018-5341-2
Zhang L, Volinia S, Bonome T et al (2008) Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 105:7004–7009. https://doi.org/10.1073/pnas.0801615105
Zehavi L, Avraham R, Barzilai A et al (2012) Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor. Mol Cancer 11:44. https://doi.org/10.1186/1476-4598-11-44
Shiah S-G, Hsiao J-R, Chang W-M et al (2014) Downregulated miR329 and miR410 promote the proliferation and invasion of oral squamous cell carcinoma by targeting Wnt-7b. Cancer Res 74:7560–7572. https://doi.org/10.1158/0008-5472.CAN-14-0978
O’Brien KP, Khan S, Gilligan KE et al (2018) Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379. Oncogene 37:2137–2149. https://doi.org/10.1038/s41388-017-0116-9
Acknowledgements
We thank Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Government of India (Grant No: EMR/2016/002314) and Department of Biotechnology (DBT), Government of India (BT/PR2423/AGR/36/700/2011) for financial support and Manipal Academy of Higher Education (MAHE) and Manipal School of Life Sciences for infrastructure support.
Funding
This study was funded by Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Government of India (Grant No: EMR/2016/002314) and Department of Biotechnology (DBT), Government of India (BT/PR2423/AGR/36/700/2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Fig. 1
Kaplan-Meier analysis on combined effect of Chr14MC expression in different cancers. a) Bladder cancer (BLCA) b) Breast cancer(BRCA) c) Kidney renal papillary cell carcinoma (KIRP) d) Pancreatic adenocarcinoma (PAAD) e) Lung squamous cell carcinoma (LUSC) f) Lung adenocarcinoma (LUAD) g) Colon adenocarcinoma (COAD) h) Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) i) Stomach adenocarcinoma (STAD) j) Head and Neck squamous cell carcinoma (HNSC). Supplementary material 9 (TIFF 3756 kb)
Supplementary Fig. 2
Kaplan-Meier analysis on combined effect of Chr14MC expression in different cancers. a) Bladder cancer b) Breast cancer c) Kidney renal papillary cell carcinoma d) Pancreatic adenocarcinoma e) Lung squamous cell carcinoma f) Liver hepatocellular carcinoma g) Lung adenocarcinoma h) Colon adenocarcinoma i) Cervical squamous cell carcinoma and endocervical adenocarcinoma j) Stomach adenocarcinoma k) Ovarian serous cystadenocarcinoma l) Head and Neck squamous cell carcinoma. Supplementary material 10 (TIFF 4976 kb)
Supplementary Fig. 3
Kaplan-Meier analysis on combined effect of Chr14MC expression in subtype of cancer a) Breast cancer PR Negative(HR=2.69, 95%CI=1.04-6.99, p=0.041), b) Breast cancer PR positive (HR=4.34, 95%CI=1.91-9.87, p=0.0004) , c) Breast cancer ER Negative(HR=2.04, 95%CI=0.72-5.8, p=0.198), d) Breast cancer ER Positive(HR=4.54, 95%CI=2.06-9.98, p=0.00016), e) Lung cancer stage IA(HR=3.717e+09, 95%CI=0-inf, p=0.99), f) Lung cancer stage IB(HR=4.47, 95%CI=1.54-12.94, p=0.005), g) Lung cancer stage IIA(HR=3.03, 95%CI=0.42-21.87, p=0.27), h) Lung cancer stage IIB(HR=8.57, 95%CI=1.93-38.09, p=0.0047), i) Lung cancer stage IIIA(HR=4.68, 95%CI=0.53-41.47, p=0.16). Supplementary material 11 (TIFF 6626 kb)
Rights and permissions
About this article
Cite this article
Jishnu, P.V., Jayaram, P., Shukla, V. et al. Prognostic role of 14q32.31 miRNA cluster in various carcinomas: a systematic review and meta-analysis. Clin Exp Metastasis 37, 31–46 (2020). https://doi.org/10.1007/s10585-019-10013-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10585-019-10013-2